Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325948 | 1.00 | MKNK1 (0.36) | MKNK1MKNK2PDCD1LG2CD274 | |
| SCHEMBL29325826 | 0.72 | PDE4A (0.50) | — | |
| SCHEMBL25301974 | 0.71 | CCNT1 (0.43) | — | |
| SCHEMBL29325902 | 0.71 | SCN9A (0.33) | MKNK1MKNK2PDCD1LG2CD274 | |
| SCHEMBL25301972 | 0.71 | CCNT1 (0.43) | — | |
| SCHEMBL29325904 | 0.71 | SCN9A (0.33) | MKNK1MKNK2PDCD1LG2CD274 | |
| SCHEMBL29325838 | 0.71 | GLP1R (0.36) | — | |
| SCHEMBL31039775 | 0.70 | CCNK (0.34) | — | |
| SCHEMBL29325869 | 0.70 | MAPK10 (0.36) | MKNK2 | |
| SCHEMBL24696092 | 0.69 | IL1B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | MKNK1 1174/4885MKNK2 719/4885PDCD1LG2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.